Plant-Derived Nanovesicles as a Cross-Kingdom Therapeutic Approach for T2DM and Related Metabolic Disorders: Current Evidence and Future Perspectives
Journal of Agricultural and Food Chemistry · 2026
DOI: 10.1021/acs.jafc.6c05063 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Agricultural and Food Chemistry, 2026. Verfasst von Yang Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Laboratory Medicine of Jiangsu Province, Department of Laboratory Medicine, School of Medicine, Jiangsu University, 301 Xuefu Road,…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metabolic Diseases, Plant Extracts, Plants. Die Arbeit nennt 202 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions, Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application.
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is increasingly viewed as a systemic metabolic disorder rather than as an isolated glycemic defect. It is closely linked to obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), sharing mechanisms such as insulin resistance, chronic inflammation, and interorgan crosstalk among the gut, liver, adipose tissue, pancreas, and central nervous system. Plant-derived nanovesicles (PDNVs) are emerging cross-kingdom nanoplatforms with the potential to modulate metabolic and inflammatory signaling. Evidence from T2DM, obesity, and MASLD models suggests that PDNVs can improve metabolic homeostasis by reprogramming metabolism and reducing inflammation. PDNVs may modulate organ axes, particularly gut–liver and gut–brain axes, and potentially adipose–liver and liver–pancreas axes, partly via context- and tissue-dependent regulation of AMPK-, PI3K-AKT-, and SIRT1-related pathways. Strategies such as structural engineering, surface functionalization, and cargo loading optimization may further enhance the stability, bioavailability, and targeting capacity of PDNVs, thereby supporting their application in metabolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Laboratory Medicine of Jiangsu Province, Department of Laboratory Medicine, School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang, Jiangsu212013, China.
- Clinical Medical Laboratory Center, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu225300, China.
- Shanghai TCM-Integrated Hospital, Shanghai University of TCM, Shanghai200082, China.
- Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu215300, China.
Förderung
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application
Zitieren
APA
Yu, Y., Shan, Y., Chen, Y., Ding, L., & Qian, H. (2026). Plant-Derived Nanovesicles as a Cross-Kingdom Therapeutic Approach for T2DM and Related Metabolic Disorders: Current Evidence and Future Perspectives. Journal of Agricultural and Food Chemistry. https://doi.org/10.1021/acs.jafc.6c05063
Vancouver
Yu Y, Shan Y, Chen Y, Ding L, Qian H. Plant-Derived Nanovesicles as a Cross-Kingdom Therapeutic Approach for T2DM and Related Metabolic Disorders: Current Evidence and Future Perspectives. Journal of Agricultural and Food Chemistry. 2026. doi:10.1021/acs.jafc.6c05063
BibTeX
@article{Yu2026,
author = {Yu, Yang and Shan, Yunjie and Chen, Yinjie and Ding, Lingling and Qian, Hui},
title = {Plant-Derived Nanovesicles as a Cross-Kingdom Therapeutic Approach for T2DM and Related Metabolic Disorders: Current Evidence and Future Perspectives},
journal = {Journal of Agricultural and Food Chemistry},
year = {2026},
doi = {10.1021/acs.jafc.6c05063}
}
EUVIMED